Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms

NCT04192916 is registered in ClinicalTrials.gov with FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS as lead sponsor.

NCT NCT04192916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04192916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
Lead sponsor
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Phase
Observational
Overall status
Completed
Start date
September 1, 2019
Completion date
December 31, 2020
Enrollment
442 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

myeloproliferative neoplasm